The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients. (SORT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01295021
First received: February 3, 2011
Last updated: June 7, 2013
Last verified: June 2013
  Purpose

The purpose of this NIS is to assess the prevalence of sympathetic overactivity in patients with newly diagnosed essential hypertension.


Condition
Essential Hypertension

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A Non Interventional, Cross Sectional, Study on the Prevalence of Sympathetic Overactivity in Hypertensive Patients.

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Prevalence of SO in newly diagnosed hypertensive patients [ Time Frame: Visit 1-3: heart rate & Blood pressure, treatment presribed by physician. The interval between visit 1 and visit 2 is upto 4 weeks and interval between visit 2 & visit 3 is upto 4 weeks depending on Investigators discretion. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Association of SO and heart rate. [ Time Frame: Visits 1-3 ] [ Designated as safety issue: No ]
  • Subjective symptoms noticed by the doctor. [ Time Frame: 1st visit ] [ Designated as safety issue: No ]
  • To record the drugs used in the treatment of patients diagnosed with hypertension. [ Time Frame: Visits 1-3 ] [ Designated as safety issue: No ]

Enrollment: 1514
Study Start Date: February 2011
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Detailed Description:

MC MD

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Primary hypertensive patients

Criteria

Inclusion Criteria:

  • Newly diagnosed essential hypertension patients will be eligible for the study.
  • Average of two or more systolic BP readings ≥ 140mmHg or diastolic BP readings ≥ 90mmHg

Exclusion Criteria:

  • History of coronary artery disease
  • History of diabetes
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01295021

  Show 99 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Dr T.N.C. Padmanabhan Dr. Padmanabhan Heart Clinic
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01295021     History of Changes
Other Study ID Numbers: NIS-CIN-DUM-2010/2
Study First Received: February 3, 2011
Last Updated: June 7, 2013
Health Authority: India: Drugs Controller General of India

Keywords provided by AstraZeneca:
The prevalence of sympathetic overactivity in hypertensive patients.

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on April 23, 2014